Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Background<br/> Anti-angiogenic agents have an established role in the treatment of metastatic colorectal cancer (CRC). It was hypothesised that their effectiveness may be augmented in earlier stage disease with a more malleable vasculature. The QUASAR 2 trial examined whether bevacizumab coul...
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Хэвлэсэн: |
Lancet
2016
|